Activated mast cells (MCs) release histamine (HA) and MCs infiltrate the liver following bile duct ligation (BDL), increasing intrahepatic bile duct mass (IBDM) and fibrosis. We evaluated the effects of BDL in MC-deficient (Kit (HEPATOLOGY 2017;65:1991 -2004 ).
C holangiocytes, the epithelial cells lining the biliary epithelium, are dynamic players during liver repair. (1) Diseases that target cholangiocytes have limited therapeutic options and include primary biliary cholangitis and primary sclerosing cholangitis (PSC). Patients with damage to bile ducts often have an increased risk for extensive liver damage and potential failure. (2, 3) The first biliary response to the mechanical rodent model of injury, bile duct ligation (BDL), is to regain bile duct mass following injury; however, extended, uncontrolled biliary hyperplasia leads to fibrosis. (2, 3) There are multiple factors that are activated during cholangiocyte proliferation following BDL, such as secretin receptor expression, (4) upregulation of vascular endothelial growth factor (VEGF), (5, 6) and escalation of histamine (HA) release. (7) (8) (9) VEGF, primarily derived from the peribiliary vascular plexus in addition to other vascular cells, is associated with cholangiocyte proliferation and cholangiocytes secrete VEGF. (5, 6) as well as HA. Canonically, fibrosis is regulated by hepatic stellate cells (HSCs), which, once activated, transform into myofibroblasts that drive collagen content higher, resulting in fibrosis. (10, 11) In addition to HSCs, cholangiocytes also play a role in paracrine signaling during fibrosis and may also contribute to activation of HSCs. (12, 13) During fibrosis, several growth factors are released from multiple cell types, including transforming growth factor-beta 1 (TGF-b1). (14) These factors contribute to hyperplasticinduced fibrosis, which can eventually lead to liver failure.
In addition to HSCs and cholangiocytes, hepatic mast cells (MCs) are also involved in fibrosis. (15) While traditionally noted for their role in allergic responses, MCs are being more recognized in a number of pathologies, (16) including liver disease, and our recent studies have demonstrated that MCs play critical and detrimental roles in BDL-induced liver damage, PSC, and cholangiocarcinoma (CCA). (17) (18) (19) MC infiltration occurs following mechanical, chemical, or toxic liver injury, and MCs migrate into CCA tumors where they promote tumor growth. (20, 21) Once activated, MCs release numerous preformed mediators like HA and other growth factors, including VEGF and TGF-b1, into the surrounding tissue microenvironment. (22, 23) In the BDL rat model, we have found that blocking MC-derived HA release with cromolyn sodium (MC stabilizer) treatment decreases hyperplasia; this same compound also decreases human CCA tumor growth and angiogenesis. (17, 18) Numerous models of MC deficiency have been developed and adapted to study allergic response, itching, cardiac function, renal response, and liver disease. Different white spotting (W) locus (c-Kit) mutant rodents have been developed and investigated as models for the analysis of MC function, including Kit W/W-v and Kit W-f/W-f mice and Kit W-s/W-s rats. (24) (25) (26) (27) Kit W/W-sh mice are MC deficient and adult mice contain no observable MC populations in tissues, including the gastrointestinal tract, respiratory system, heart, brain, skeletal muscle, spleen, and other anatomical sites. (25) No studies have been performed to understand whether the lack of MCs contributes to or regulates BDLinduced liver injury and fibrosis; thus, our aim was to examine the effects of MC depletion following BDL using MC-deficient mice.
Materials and Methods

REAGENTS AND OTHER MATERIALS
Antibodies for immunohistochemistry (IHC) and immunofluorescence (IF) were purchased from Abcam (Cambridge, MA). HA enzymatic immunoassay (EIA) kits were purchased from Cayman Chemical (Ann Arbor, MI). (28, 29) 
IN VIVO MODELS
We utilized commercially available homozygous MCdeficient C57BL/6J-Kit
) mice obtained from The Jackson Laboratory (Sacramento, CA) along with age-matched wild type mice (WT). Pair breeding was utilized to generate offspring, and only male mice were used in our study. WT and Kit W-sh mice (at least 12 weeks of age) were subjected to sham or BDL (as described, without cholecystectomy (4, 30) ) for up to 7 days, and, in separate experiments, Kit W-sh mice (at least 8 weeks of age) were injected with sterile, tagged cultured MCs (MC/9 [ATCC CRL-8306]) or 13 phosphate-buffered saline (PBS; control) before sacrifice 3 days later. Specifically, cultured MCs were tagged with PKH26 Red Fluorescent Cell Linker before injection, and mice received a single injection of sterile, cultured MCs (5 3 10 6 /0.1 mL of sterile 13 PBS) or control by tail vein injection. (31) Following euthanasia, the location (liver, lung, and spleen) of injected MCs was determined using confocal microscopy for visualization of PKH26 Red Fluorescent Cell Linker. Livers were also costained with cytokeratin-19 (CK-19) to mark bile ducts and location of injected MCs.
All mice were housed in the Baylor Scott and White Health Animal Facility and given free access to drinking water and standard chow. Animals were kept in a temperature-controlled environment with a 12/12-hour light/dark cycle, and all protocols were approved by, and strictly adhered to regulations set forth by, the local institutional animal care and use committee. From all animals (n 5 at least 6 mice from each group), we collected serum, liver blocks, and isolated cholangiocytes. (4, 7) Cholangiocyte supernatants were collected and incubated at 378C for up to 6 hours and stored for in vitro studies. (18) 
ASSESSMENT OF LIVER DAMAGE IN MODELS OF MC DEFICIENCY
We assessed liver damage in our WT and Kit W-sh mice subjected to sham or BDL surgery as well as the Kit W-sh mice injected with MCs by hematoxylin & eosin (H&E) staining as described. (4) Slides were evaluated by a blinded board-certified pathologist and scored for lobular damage, focal necrosis, and inflammation. Alanine aminotransferase (ALT) activity was measured in serum from all groups of mice using a commercially available kit (Abcam, Cambridge, MA).
EVALUATION OF BILIARY MASS AND PROLIFERATION IN MC-DEFICIENT MODELS
When BDL rats or Mdr2 -/-mice are treated with the MC stabilizer, cromolyn sodium (blocks MC HA release), biliary mass and proliferation are significantly reduced. (18, 19) Thus, we suspect that MCs are an important player in the regulation of biliary hyperplasia following BDL. We evaluated the effects of MC deficiency on intrahepatic bile duct mass (IBDM) and proliferation in both WT and Kit W-sh mice with sham or BDL surgery. IHC, real-time PCR, and western blotting (29, 30) were performed for the biliary marker, CK-19, (18, 29) to measure IBDM, and cholangiocyte proliferation was determined by Ki-67 staining. (19) 
EFFECTS OF MC DEFICIENCY ON FIBROSIS AND HSC ACTIVATION
We measured fibrosis progression and collagen deposition from both WT and Kit W-sh mice with sham or BDL surgery. Fast Green/Sirius Red, Masson's trichrome, and hydroxyproline content were assessed in liver sections and snap liver, respectively. (29) In total liver from all groups, we measured the following fibrotic markers by real-time PCR: a-smooth muscle actin (a-SMA), collagen type-1a, and fibronectin-1. (29) Because TGF-b1 is a known regulator of fibrosis, (11) we evaluated expression of TGF-b1 in total liver by real-time PCR and secretion of TGF-b1 by EIA in serum from these mice. (19) We also evaluated the effects of MC deficiency on HSC activation by IF for synaptophysin-9 (SYP-9). (32) Livers were costained with CK-19 to also visualize bile ducts.
EVALUATION OF HA SIGNALING AND SECRETION IN MC-DEFICIENT MODELS
Our previous studies have demonstrated that HA synthesis and HA receptors (HRs) are up-regulated in models of biliary damage, including BDL. (18, 29) Cholangiocytes secrete small amounts of HA (28, 29) ; however, the main source of HA release is activated MCs. To further examine the role that HA signaling has during cholestatic liver injury, we measured histidine decarboxylase (HDC) and HR expression in total liver from WT and Kit W-sh mice with sham or BDL surgery by real-time PCR. HA secretion was evaluated by EIA in serum from these mice as described. (28, 29) ASSESSMENT OF THE EFFECTS OF MC DEFICIENCY ON VASCULAR TISSUE AND VEGF SIGNALING VEGF has been shown to play a role in biliary response to BDL, and cholangiocytes express VEGF receptors and secrete VEGF. (5, 6) However, the peribiliary vascular plexus and vascular cells are the largest source of VEGF in the liver; therefore, we evaluated these factors in our models. Evaluation of H&E staining for peribiliary glands was performed in liver sections from WT and Kit W-sh mice with sham or BDL surgery. IF was performed in liver sections from WT and Kit W-sh mice with sham or BDL surgery for von Willebrand factor (vWF) expression. (33) Liver sections were costained with CK-19 to distinguish bile ducts. In total liver from WT and Kit W-sh mice with sham or BDL surgery, we measured expression of VEGF-C and vWF by real-time PCR.
MEASUREMENT OF BILIARY PROLIFERATION, FIBROSIS, AND HSC ACTIVATION FOLLOWING INTRODUCTION OF MCs INTO DEFICIENT MICE
Because our previous work has demonstrated that MCs infiltrate the liver following BDL and contribute to FIG. 1. Liver damage was assessed by H&E staining in liver sections from all groups. BDL WT mice displayed increased focal necrosis (infarct) in zone 2 indicated by black arrowheads (upward of 4%-5% of lobule) and portal inflammatory changes that are consistent with obstruction. An increase in mostly large bile ducts is also observed following BDL (indicated by black arrows). In Kit W-sh sham mice and Kit W-sh mice subjected to BDL, the presence of necrosis/liver infarcts was absent (A). ALT activity was significantly increased in BDL WT compared to sham WT, whereas ALT activity in both sham and BDL Kit W-sh sham mice was similar to sham WT (B). In livers of Kit W-sh mice injected with MCs, there were no visible areas of liver necrosis/infarcts or portal inflammation/damage when compared to Kit W-sh mice injected with 13 PBS (C) and ALT levels remain unchanged (D). Data are expressed as mean 6 SEM of at least six experiments for ALT. *P < 0.05 versus sham WT mice; # P < 0.05 versus BDL WT mice. Images are 103 magnification. Abbreviations: PV, portal vein; CV, central vein.
biliary hyperplasia and fibrosis, (18) our final in vivo experiments were performed to determine the implications of the reintroduction of MCs into deficient models. Kit W-sh mice were injected with 13 PBS or sterile, cultured MCs through tail vein, (31) and IBDM, proliferation, fibrosis, and vascular cell response were all evaluated as described above. Localization of injected MCs was determined by confocal microscopy in lung, liver, and spleen tissues.
EVALUATION OF THE EFFECTS OF MC DEFICIENCY ON HSC ACTIVATION, IN VITRO
Our work demonstrates that MCs interact with and alter cholangiocyte response, which leads to fibrosis progression. (18, 19) To determine whether there is a synergistic effect between MCs, cholangiocytes, and HSCs, we stimulated cultured human HSCs (hHSCs) (19) with isolated cholangiocyte supernatants collected from WT and Kit W-sh mice subjected to sham or BDL surgery or cholangiocyte supernatants from Kit W-sh mice injected with MCs. hHSCs were stimulated with 100 lL of cholangiocyte supernatant for 24 hours, and activation was measured by a-SMA expression by real-time PCR.
STATISTICAL ANALYSIS
All data is expressed as mean 6 SEM. Groups were analyzed by the Student unpaired t test when two groups are analyzed or a two-way ANOVA when more than 2 groups are analyzed, followed by an appropriate post hoc test. P < 0.05 was considered significant.
Results
HEPATIC INJURY IS AMELIORATED IN BDL Kit
W-sh MICE BDL WT mice displayed increased focal necrosis (infarct) in zone 2 (upward of 4%-5% of lobule) and
FIG. 2. IBDM (A,B)
and Ki-67 (C) were evaluated in liver sections from WT and Kit W-sh subjected to sham and BDL surgery. We found that IBDM (shown by CK-19 staining (A) and western blotting (B)) and proliferation (indicated by Ki-67 staining (C)) increased in BDL WT mice when compared to sham WT mice, whereas both IBDM and the number of proliferating cholangiocytes were reduced in BDL Kit W-sh mice. Semiquantitative data are expressed as mean 6 SEM of at least 10 experiments and at least eight experiments for western blotting. *P < 0.05 versus sham WT mice; # P < 0.05 versus BDL WT mice. Images are 103 magnification for CK-19 and 203 for portal inflammatory, changes that are consistent with obstruction (indicated by black arrowheads). An increase in mostly large bile ducts is also observed following BDL (indicated by black arrows). In BDL Kit W-sh mice, the degree of focal necrosis (infarct) was absent compared to BDL WT (Fig. 1A) . ALT activity was significantly up-regulated in BDL WT mice, but this was completely ablated in BDL Kit W-sh mice that demonstrate ALT levels similar to sham WT (Fig.  1B) . In livers of Kit W-sh mice injected with MCs, there were no visible areas of liver infarcts/focal necrosis or portal inflammation/damage compared to Kit W-sh mice injected with 13 PBS (Fig. 1C) . Furthermore, ALT levels were not significantly altered after MC injection compared to controls, suggesting that introduction of MCs does not mimic BDL-induced damage (Fig. 1D ).
BILIARY MASS AND PROLIFERATION ARE SIGNIFICANTLY REDUCED IN BDL Kit W-sh MICE
In BDL Kit W-sh mice, there was an overall reduction of IBDM compared to BDL WT mice ( Fig. 2A) . These results were further confirmed by real-time PCR (Supporting Fig. S1A ) and western blotting (Fig. 2B ) that displayed a similar trend to the IHC results.
As expected, biliary proliferation (indicated by red arrows) was significantly decreased in BDL Kit W-sh mice compared to BDL WT (Fig. 2C) . Cholangiocyte proliferation was similar between sham WT and Kit W-sh mice (Fig. 2C) . 
FIBROSIS AND HSC ACTIVATION ARE DEPENDENT UPON MCs
Collagen deposition was dramatically reduced in BDL Kit W-sh mice compared to BDL WT mice, as shown by Masson's trichrome and Fast Green/Sirius Red staining (Fig. 3A,B, respectively) . Semiquantification of Fast Green/Sirius Red staining showed a significant decrease in collagen deposition in BDL Kit W-sh mice compared to BDL WT (Fig. 3C ). Hydroxyproline content was significantly reduced in BDL Kit W-sh mice compared to BDL WT (Fig. 3D ). Expression of a-SMA, fibronectin-1, and collagen type-1a increased in BDL WT mice compared to sham WT, whereas these markers were decreased in BDL Kit W-sh mice compared to BDL WT mice (Supporting Fig. S2) .
In BDL Kit W-sh mice, there was a significant reduction in both TGF-b1 expression (Fig. 4A ) and secretion (Fig. 4B) compared to BDL WT. SYP-9 protein expression was up-regulated in BDL WT; however, in BDL Kit W-sh mice, there was a decrease in HSC activation compared to BDL WT (Fig. 4C) .
HA SIGNALING AND SECRETION ARE DECREASED IN BDL
In BDL Kit W-sh mice, there was a decrease in HRs and HDC compared to BDL WT (Supporting Fig.  S3A,B) . Similarly, HA serum release was increased in BDL WT mice compared to sham WT, whereas HA release decreased in BDL Kit W-sh mice compared to BDL WT (Supporting Fig. S3C ).
LOSS OF MCs REDUCES PERIBILIARY GLAND PRESENCE AND vWF AND VEGF EXPRESSION
Following BDL in WT mice, there was an increase in the presence of peribiliary glands (marked by black arrows) found in close proximity to large bile ducts (indicated by the white arrow) when compared to sham WT mice (Fig. 5A) . However, in both sham and BDL Kit W-sh mice, there was no visible evidence of peribiliary glands (Fig. 5A ) compared to BDL WT. Furthermore, VEGF-C expression was significantly reduced in BDL Kit W-sh mice compared to BDL WT (Fig. 5B) . IF for vWF demonstrated an increase in BDL WT mice compared to WT, and in BDL Kit W-sh mice, there was a marked decrease in expression of vWF compared to BDL WT (Fig. 5C) . Similarly, vWF gene expression was increased in BDL WT mice compared to WT, and in BDL Kit W-sh mice, there was a marked decrease in expression of vWF compared to BDL WT (Fig. 5D ). These data indicate that MCs not only influence the biliary tree, but also the vascular bed during BDL-induced liver damage.
INTRODUCTION OF MCs INTO DEFICIENT MICE INCREASES BILIARY HYPERPLASIA, FIBROSIS, AND VASCULAR CELL PRESENCE
Unpublished observations from our lab have demonstrated that injection of cultured MCs into either WT mice or HDC knockout mice, which have very low numbers of MCs, increases biliary proliferation and fibrosis. In our present study using MC-deficient mice, we found that injected MCs were in close proximity to bile ducts (Supporting Fig. S4) , and IBDM and biliary proliferation are significantly increased in Kit W-sh mice injected with MCs compared to mice injected with 13 PBS, as shown by CK-19 and Ki-67 IHC (Fig. 6A,B) . CK-19 IHC was further confirmed by real-time PCR and western blotting that displayed a similar trend to the IHC results (Supporting Fig.  S1B,C) . Similar to BDL WT, there was an increase in vWF expression in Kit W-sh mice injected with MCs compared to 13 PBS injection, as shown by IF (Fig.  6C) . Furthermore, VEGF-C gene expression increased in Kit W-sh mice injected with MCs compared to 13 PBS injection (Fig. 6D) . Taken together, these data strongly suggest that reintroduction of MCs alters the proliferative capacity of cholangiocytes and the vascular bed in MC-deficient mice.
In Kit W-sh mice injected with MCs, collagen deposition was increased, as shown by Masson's Trichrome staining (Fig. 7A) , and collagen type-1a and fibronectin-1 expression also increased along with hydroxyproline content (Fig. 7B,C) . TGF-b1 expression and secretion were significantly increased in Kit W-sh mice injected with MCs compared to 13 PBS injection (Fig. 7D) . These data all pinpoint MCs as key components of biliary hyperplasia and fibrosis progression. It should be noted that these data, coupled with the H&E and ALT levels (Fig. 1C,D) , which showed no visible alterations in liver morphology and function, suggest that MC injection increases proliferation and fibrosis, but does not mimic the damage induced by BDL. 
EFFECTS OF MC DEFICIENCY ON BILIARY CELLS AND HSCs, IN VITRO
In vitro, we found that MCs and cholangiocytes work synergistically to contribute to activation of HSCs. Specifically, when cultured hHSCs were treated with cholangiocyte supernatants collected from BDL WT mice, there was increased expression of a-SMA when compared to hHSCs treated with sham WT cholangiocyte supernatants (Fig. 8) , suggesting that factors released from cholangiocytes following BDL alter HSC response. In contrast, when hHSCs were treated with cholangiocyte supernatants collected from sham or BDL Kit W-sh mice, a-SMA expression decreased (Fig. 8) . Last, when hHSCs were stimulated with cholangiocyte supernatants from Kit W-sh mice injected with MCs, a-SMA increased when compared to all of the other groups, including BDL WT treatments (Fig. 8) . These findings indicate that MC presence alters cholangiocyte response, thus impacting HSC activation, which is a critical step in fibrosis development.
Discussion
Our investigation of the paracrine role that MCs play during liver injury and repair has revealed that there is a critical pathological function induced by MC presence that contributes to biliary hyperplasia, promotes fibrosis progression, and alters the vascular bed. Whereas BDL is an injury that directly damages bile duct and cholangiocytes, the peripheral damage that occurs to the biliary tree extends further and involves numerous components, including infiltration of MCs to injured bile ducts where they surround reactive cholangiocytes. (18) Once infiltration of MCs occurs, there is a dynamic series of events that induces biliary hyperplasia and an increase of HA release (from MCs and cholangiocytes) and induction of VEGF and TGF-b1.
Biliary hyperplasia following BDL is the liver's first attempt to repair the injured bile duct, and our data suggest that MCs are also critical to this event given that there is a dramatic decrease in IBDM and proliferation in BDL Kit W-sh mice compared to BDL WT mice. In addition, reintroduction of MCs into MCdeficient mice resulted in large increases in both IBDM and cholangiocyte proliferation, suggesting that MCs are essential during these events. In support of our work, it has been demonstrated that introduction of MCs into MC-deficient mice promotes muscle cell hyperplasia and hypertrophy during eosinophilic esophagitis, (34) and MCs contribute to hepatic steatosis, which was ameliorated in MC-deficient mice. (35) The role that MCs play in tissue fibrosis is controversial. Studies have demonstrated that (1) MCs promote tissue fibrosis, (2) loss of MCs induces fibrosis, leading to a worsening condition, and (3) MCs play no real role in tissue fibrosis. A study using Ws/Ws rats that are MC-deficient found vigorous interstitial fibrosis in the kidney compared to the control, suggesting that, in this model, MCs are beneficial to the fibrotic process. (36) In support of our findings, it has been demonstrated that MCs can promote and drive cardiac fibrosis and eventual failure, and that MC-deficient mice are protected from cardiac fibrosis and heart failure. (37, 38) In contrast to our current work, an early study by Sugihara et al. demonstrated that MCs have no consequence on the development of liver fibrosis in rats and mice, (39) whereas our present studies indicate that MC introduction (shown by MC injection into deficient mice) induces robust fibrosis and there is decreased fibrotic progression in BDL Kit W-sh compared to BDL WT mice. One prominent discrepancy between these studies is the fact that in Sugihara et al.'s study, rats and mice that underwent bile duct resection were not euthanized and tissue collected until 21 days postsurgery; therefore, the reaction of the biliary tree and infiltration of MCs during early fibrosis events were not evaluated. (39) In contrast, in our study, we evaluated BDL-induced damage no later than 7 days, when the biliary tree has been shown to be fully reactive to damage and MC infiltration is increased. (18) Another difference is the rodent model of MC deficiency used; the other researchers chose Ws/Ws rats and male WBB6F 1 One prominent driver of collagen production in fibroblasts and a contributor to fibrosis is TGF-b1, which is also found within MCs and can be released upon activation. Release of TGF-b1 perpetuates fibroblasts to transform into myofibroblasts, inducing fibrosis during autoimmune diseases. We found that ablation of MCs significantly reduces BDL-induced TGF-b1 expression and secretion. In addition, TGF-b1 levels were increased in Kit W-sh mice injected with cultured MCs, supporting the concept that MCs are an important source of TGFb1 during fibrosis progression. To support this, it has been shown that HA or angiotensin released from MCs induces secretion of TGF-b1 from fibroblasts that, in turn, increases collagen synthesis and pulmonary fibrosis induction. When MCs were absent, these events were inhibited. (40) Inflammation is an important component to the repair process in myocardial infarction, and implanted MCs (from WT mice) into MC-deficient mice increases angiogenesis and cardiac function through augmented fibroblast activity and transformation that was TGF-b1 dependent, (41) again pinpointing MCregulated TGF-b1 as a key player in fibrosis. The full understanding of the contribution of MCs on liver fibrosis is not completely defined; however, we present strong data herein to show that MCs play a critical and detrimental role in fibrosis through TGF-b1.
MCs release numerous factors, but the main component of MCs is HA, which has been recognized now to be more than just a mediator of allergic events. (14, 16) We have demonstrated in numerous studies that HA is a trophic, growth-promoting factor that induces biliary hyperplasia, fibrosis, and CCA progression. (8, 9, 28) Cholangiocytes secrete minimal amounts of HA and are able, through autocrine signaling, to regulate CCA growth (28) ; however, MCs are the major producers of HA in the body. Stabilization of MCs using cromolyn sodium has demonstrated that inhibition of MC-derived HA decreases biliary hyperplasia, fibrosis, and CCA growth, pinpointing MC-derived HA as a culprit in various cholangiopathies. (17) (18) (19) In our current study, we measured HA synthesis, HR expression, and HA secretion in our rodent models. As expected, all of these factors were up-regulated in BDL WT, but reduced in BDL Kit W-sh mice, further suggesting that HA itself is a driver of biliary hyperplasia and fibrosis. Although our mice are MC-deficient, they are still receiving histidine in their standard chow, and because cholangiocytes secrete small amounts of HA, (28, 29) this may account for the minimal amount of HA found in the serum and is consistent with other studies using MCdeficient models or HDC-deficient mice. (29) Besides being a growth-promoting factor, HA also regulates other factors, including VEGF, during BDL-induced injury. (29, 30) The peribiliary plexus is a dynamic structure that supports the nutritional needs of the biliary tree and provides the largest source of VEGF in the liver, although cholangiocytes secrete VEGF and express VEGF-R2 and VEGF-R3. MCs also express VEGF receptors and produce VEGF when activated. (42, 43) In melanoma tumor growth, activation of MCs by immunoglobulin E induces VEGF release that promotes tumor growth, demonstrating that MCs can regulate cell growth through VEGF. (43) In our study, we found that BDL Kit W-sh mice have lower levels of VEGF-C, and, furthermore, the vascular bed is altered in BDL Kit W-sh mice, as shown by the diminished presence of peribiliary glands and decreased expression of vWF. In support of the concept that MCs can influence peribiliary gland development, a study examining mammary glands in Kit W-sh mice found that the development of glands, but not the function, was altered in MC-deficient mice compared to WT counterparts. (44) These mice were still able to lactate and function properly, even though the mammary glands were significantly altered during development. The changes demonstrated in our current study regarding IBDM and biliary proliferation, coupled with the presence or absence of peribiliary glands, suggests that the peribiliary glands are not the sole source of proliferating cholangiocytes. This is supported by numerous studies demonstrating that other factors, including secretin, serotonin, and VEGF, are secreted from cholangiocytes, which can subsequently influence biliary proliferation in both normal and damaged states. (4, 6, 45) Furthermore, Kit W-sh mice injected with MCs had increased VEGF-C expression as well as an increase in vascular cell activation, as shown by vWF expression. Ghosh et al. found no difference in angiogenic signaling in MC-deficient mice, WBB6F1-W/W(V), compared to controls following implantation of cotton threading to induce granulation tissue formation; however, HDC knockout mice displayed marked alterations in angiogenic signaling. (46) Our study also demonstrates no significant difference in vascular remodeling between sham WT and sham Kit W-sh mice, implying that the effect of MCs is enhanced during pathological conditions. These findings demonstrate that there is a significant loss of biliary reaction in MC-deficient mice that alters both proliferation and the response of the vascular bed.
Our group and others have demonstrated that cholangiocytes are important in the progression of fibrosis, (13, 18, 19) and our current study also reveals that MCs can alter cholangiocyte response, as shown by IBDM and proliferation. Whether MCs, cholangiocytes, and HSCs work together to drive fibrosis is not fully known. Our data demonstrate that hHSCs express increased amounts of a-SMA when stimulated with cholangiocyte supernatants collected from BDL WT mice, which is subsequently decreased in hHSCs treated with Kit W-sh supernatants from mice subjected to sham or BDL. When hHSCs are stimulated with cholangiocyte supernatant from Kit W-sh mice injected with MCs, there is a dramatic increase in hHSC a-SMA expression that exceeds the BDL WT treatment, strongly suggesting that MCs are key regulators of cholangiocyte response and HSC activation that, together, promote fibrosis.
From a clinical perspective, depletion of MCs throughout the whole body is not a likely healthy scenario given that they are necessary during wound healing, but mechanisms to block MCs and the mediators that they release may rescue the liver from biliary damage, fibrosis, and vascular bed alteration. Cromolyn sodium is one such drug that targets MC-derived HA, and treatment with cromolyn sodium inhibits biliary hyperplasia and fibrosis, (18, 19) but there are other factors to consider as we have described in our study, including TGF-b1 and VEGF. Potential candidates for therapy might include drugs to target and inhibit MC migration (stem cell factor inhibitors) in conjunction with compounds that block VEGF or TGF-b1 release from MCs. Furthermore, microRNAs are being investigated as potential mechanisms to regulate MC activation. For example, microRNA-223 targets insulin-like growth factor 1 receptor in MCs, promoting degranulation and decreasing the phosphoinositide 3-kinase/protein kinase B pathway. (47) In conclusion, we have shown that MCs are prominent regulators of biliary hyperplasia, liver fibrosis, and vascular bed dysfunction demonstrated by both the BDL model and through direct injection of MCs into deficient mice (Supporting Fig. S5 ). Our studies reveal a synergistic interplay between MCs, cholangiocytes, and HSCs, demonstrating the importance of cellular paracrine signaling during disease progression. Considering that MCs infiltrating the liver following damage are not resident liver cells, inhibition or knockdown of MCs or MC components are likely to be effective therapeutically for patients suffering from cholangiopathies. Our study should motivate the future investigation of modulation of MCs during cholangiopathies and fibrosis.
